Innocare Pharma Ltd. A

InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE

InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability

Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety

InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit

InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China